This is a working overview of glucagon receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-02. Anything still debated is marked as such rather than presented as settled.
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
| Property | Value | Notes |
|---|---|---|
| 长期储存温度 | 约 -20°C 或更低 | 冻干粉常见保存条件 |
| 复溶溶剂 | 注射用水或指定缓冲液 | 按方案或说明书执行 |
| 容器材质 | 低吸附聚丙烯 | 减少多肽在管壁的吸附损失 |
| 主要降解路径 | 脱酰胺、氧化、聚集 | 由序列与工艺条件共同决定 |
| 追溯材料 | 分析证书与批次记录 | 用于来源与纯度核实 |
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
The 550-metre (1,804 ft) Crystal Palace pneumatic railway was exhibited at the Crystal Palace in 1864. This was a prototype for a proposed Waterloo and Whitehall Railway that would have run under the River Thames linking Waterloo and Charing Cross. Digging commenced in 1865 but was halted in 1868 due to financial problems. In 1867 at the American Institute Fair in New York, Alfred Ely Beach demonstrated a 100-foot (30 m) long, 6-foot (1.8 m) diameter pipe that was capable of moving 12 passengers plus a conductor. One year after New York City's first-ever elevated rail line went into service; in 1869, the Beach Pneumatic Transit Company of New York secretly constructed a 312-foot (95 m) long, 8.9-foot (2.7 m) diameter pneumatic subway line under Broadway, to demonstrate the possibilities of the new transport mode. The line only operated for a few months, closing after Beach was unsuccessful in getting permission to extend it – Boss Tweed, a corrupt influential politician, did not want it to go ahead as he was intending to personally invest into competing schemes for an elevated rail line.
=== Gastrointestinal and accessory organs === Accumulation of amyloid proteins in the gastrointestinal system may be caused by a wide range of amyloid disorders and have different presentations depending on the degree of organ involvement. Potential symptoms include weight loss, diarrhea, abdominal pain, heartburn (gastrointestinal reflux), and GI bleeding. Amyloidosis may also affect accessory digestive organs including the liver, and may present with jaundice, fatty stool, anorexia, fluid buildup in the abdomen, and spleen enlargement. Accumulation of amyloid proteins in the liver can lead to elevations in serum aminotransferases and alkaline phosphatase, two biomarkers of liver injury, which is seen in about one third of people. Liver enlargement is common. In contrast, spleen enlargement is rare, occurring in 5% of people. Splenic dysfunction, leading to the presence of Howell-Jolly bodies on blood smear, occurs in 24% of people with amyloidosis. Malabsorption is seen in 8.5% of AL amyloidosis and 2.4% of AA amyloidosis. One suggested mechanism for the observed malabsorption is that amyloid deposits in the tips of intestinal villi (fingerlike projections that increase the intestinal area available for absorption of food), begin to erode the functionality of the villi, presenting a sprue-like picture.
Soft tissue is tissue in the body that connects and surrounds or supports internal organs and bones, and includes muscle, tendons, ligaments, fat, fibrous tissue, lymph and blood vessels, fasciae, and synovial membranes. Soft tissue is not hardened by the processes of ossification or calcification such as bones and teeth. It is sometimes defined by what it is not – such as "nonepithelial, extraskeletal mesenchyme exclusive of the reticuloendothelial system and glia".
In contrast, large vancomycin can not pass through porins and is thus ineffective for gram-negative bacteria. The size and number of porins are different in different bacteria. As a result of the two factors—size of penicillin and porin—gram-negative bacteria can be unsusceptible or have varying degree of susceptibility to specific penicillin.
== Provisions == The One Big Beautiful Bill Act includes hundreds of provisions, and over a ten-year period is estimated to add roughly $3 trillion to the national debt and to cut approximately $4.46 trillion in tax revenue.
Sources: en.wikipedia.org
The canal remained a remote and sparsely populated wilderness, unchanged over centuries. The Upper Orinoco, at its junction with the Casiquiare, was over a thousand miles from the sea and still more than a quarter mile wide. The expedition proceeded to Esmeralda, a remote mission at the foot of the Sierra Duida. The settlement was isolated and regarded as a place of hardship, plagued by insects and food shortages. Esmeralda was famous for the production of curare, a potent poison prepared by local Natives. Humboldt and Bonpland observed its preparation and collected samples, narrowly avoiding accidental poisoning. Hostile indigenous groups upriver from Esmeralda forced the party to abandon plans to explore the Orinoco’s source. Weakened by insects, poor food, and cramped conditions, the expedition left Esmeralda on 23 May. They traveled rapidly downstream, reaching the Atures rapids by the end of May. Humboldt visited the cavern of Ataruipe, discovering hundreds of well-preserved Native skeletons. He collected several for scientific study, which later caused difficulties with locals who recognized the resin used in their preparation. The expedition passed through the rapids for the last time. Father Zea left to rejoin his mission. Many of the local Natives suffered from illness. Bonpland soon fell sick but continued to collect plants despite worsening health. In early June, the group reached Uruana and encountered the Ottomac people. Humboldt described them as unruly, hard to govern, and addicted to a hallucinogenic drug.
== History and uses == Azinphos-methyl is a neurotoxin derived from nerve agents developed during World War II. It was first registered in the US in 1959 as an insecticide and is also used as active ingredient in organophosphate (OP) pesticides. It is not registered for consumer or residential use. It has been linked to health problems of farmers who apply it, and the U.S. Environmental Protection Agency (EPA) considered a denial of reregistration, citing, “concern to farm workers, pesticide applicators, and aquatic ecosystems. The use of AZM has been fully banned in the USA since 30 September 2013, ending a phase-out period of twelve years. Azinphos-methyl has been banned in the European Union since 2006 and in Turkey since 2013. The New Zealand Environmental Risk Management Authority made a decision to phase out azinphos-methyl over a five-year period starting from 2009. In 2014, it was still used in Australia and partly in New Zealand.
He was also involved in Meeting Se Meeting Tak, an unreleased project. His final major acting role during this period was in Pyaar Impossible!(2010). That same year, he participated as a contestant on the reality television show Khatron Ke Khiladi.
AAA proteins are not restricted to eukaryotes. Prokaryotes have AAA which combine chaperone with proteolytic activity, for example in ClpAPS complex, which mediates protein degradation and recognition in E. coli. The basic recognition of proteins by AAAs is thought to occur through unfolded protein domains in the substrate protein. In HslU, a bacterial ClpX/ClpY homologue of the HSP100 family of AAA proteins, the N- and C-terminal subdomains move towards each other when nucleotides are bound and hydrolysed. The terminal domains are most distant in the nucleotide-free state and closest in the ADP-bound state. Thereby the opening of the central cavity is affected. AAA proteins are involved in protein degradation, membrane fusion, DNA replication, microtubule dynamics, intracellular transport, transcriptional activation, protein refolding, disassembly of protein complexes and protein aggregates.
Sources: en.wikipedia.org
Hippocrates in his writings discussed the use of silver in wound care. At the beginning of the twentieth century surgeons routinely used silver sutures to reduce the risk of infection. In the early 20th century, physicians used silver-containing eyedrops to treat ophthalmic problems, for various infections, and sometimes internally for diseases such as tropical sprue, epilepsy, gonorrhea, and the common cold. During World War I, soldiers used silver leaf to treat infected wounds. In the 1840s, founder of gynecology J. Marion Sims employed silver wire, which he had a jeweler fashion, as a suture in gynecological surgery. This produced very favorable results when compared with its predecessors, silk and catgut. Prior to the introduction of modern antibiotics, colloidal silver was used as a germicide and disinfectant. With the development of modern antibiotics in the 1940s, the use of silver as an antimicrobial agent diminished, although it retains some use in medicinal compounds today. Silver sulfadiazine (SSD) is a compound containing silver and the antibiotic sodium sulfadiazine, which was developed in 1968.
== Preparation and purification == The isotopes of nobelium are mostly produced by bombarding actinide targets (uranium, plutonium, curium, californium, or einsteinium), with the exception of nobelium-262, which is produced as the daughter of lawrencium-262. The most commonly used isotope, 255No, can be produced from bombarding curium-248 or californium-249 with carbon-12: the latter method is more common. Irradiating a 350 μg cm−2 target of californium-249 with three trillion 73 MeV carbon-12 ions per second for ten minutes can produce around 1200 nobelium-255 atoms. Once the nobelium-255 is produced, it can be separated out similarly as used to purify the neighboring actinide mendelevium. The recoil momentum of the produced nobelium-255 atoms is used to bring them physically far away from the target from which they are produced, bringing them onto a thin foil of metal (usually beryllium, aluminium, platinum, or gold) just behind the target in a vacuum: this is usually combined by trapping the nobelium atoms in a gas atmosphere (frequently helium), and carrying them along with a gas jet from a small opening in the reaction chamber. Using a long capillary tube, and including potassium chloride aerosols in the helium gas, the nobelium atoms can be transported over tens of meters. The thin layer of nobelium collected on the foil can then be removed with dilute acid without completely dissolving the foil.
Psychiatric disturbances: anxiety CNS reactions: somnolence, malaise, vertigo, paresthesia, headache, apathy Ear problems: hearing loss Heart problems: tachycardia GI reactions: xerostomia, taste disorders, diarrhoea, dyspepsia, upper quadrant pain, lip paresthesia, nausea, vomiting, constipation, excessive thirst Hepatic and bile ducts reactions: hepatic insufficiency, hepatitis, increased liver enzymes Skin and soft tissue reactions: rash, pruritus, urticaria, flushing, blistering, lumps, exudation, erythema multiforme Renal reactions: urinary retention Reproductive system reactions: dysmenorrhoea, mastitis, gynecomastia in males, breast pain
In February 2023, Peña said in an interview with Folha de S.Paulo that the military dictatorship of Alfredo Stroessner had resulted in "more than 50 years of stability in Paraguay". He further asserted that Stroessner, who came to power as a result of a coup d'état, had come to a power as a result of a "political agreement". Peña's comments were criticised by opposition politicians and activists, and he was accused of trying to attract conservative and ultraconservative voters within the Colorado Party.
Oenococcus oeni, the LAB species most often desired by winemakers to carry out malolactic fermentation, can be found in the vineyard, but often at very low levels. While moldy, damaged fruit has the potential to carry a diverse flora of microbes, the LAB most often found on clean, healthy grapes after harvest are species from the Lactobacillus and Pediococcus genera. After crushing, microbiologists usually find populations under 103 colony forming units/mL containing a mix of P. damnosus, L. casei, L. hilgardii, and L. plantarum, as well as O. oeni. For musts that do not receive an early dose of sulfur dioxide to "knock back" these wild populations of LAB, this flora of bacteria compete with each other (and the wine yeasts) for nutrients early in fermentation. In the winery, multiple contact points can be home to native population of LAB including oak barrels, pumps, hoses, and bottling lines. For wines where malolactic fermentation is undesirable (such as fruity white wines), the lack of proper sanitation of wine equipment can lead to the development of unwanted MLF and result in wine faults. In cases of oak barrels where full and complete sanitation is almost impossible, wineries often mark barrels that have contained wines going through MLF and keep them isolated from "clean" or brand new barrels that they can use for wines that are not destined to go through MLF.
Sources: en.wikipedia.org
常用质谱测定分子量，再结合肽图或序列分析验证一级结构。单一检测手段一般难以排除结构相近的类似物。多种方法相互印证更为可靠。
低温可以降低水解与聚集的速率，从而延缓降解进程。温度反复波动本身也可能造成相变与样品损失。稳定的储存条件是可重复结果的前提。
分析证书、批次编号、所用检测方法与结果，以及标称储存条件。缺少方法细节的报告难以独立复核。记录完整性决定了追溯能否成立。
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.